News and Press Releases
Prostate Cancer
-
Tucson startup looks to human trials for drug to treat lung inflammation
Jan 2022
-
Preclinical studies show Aqualung Therapeutic’s eNAMPT- targeting ALT-100 mAb to reduce severity of aggressive prostate cancer
Jan 2022
-
Aqualung Therapeutics Corp. Closes a $2.5M Convertible Note Raise With a Committed Series A Lead Investor
Jan 2022
-
CEO & Founder of Aqualung Therapeutics Corp., Joe G.N. Garcia MD to Present Corporate Update at the Annual Biotech Showcase
Dec 2021
-
Aqualung Therapeutics Selected to Present at the Phoenix 2021 Venture Madness Competition
August 2021
-
Aqualung Therapeutics Corp. Publication Supports eNAMPT as Both Biomarker & Therapeutic Target in Prostate Cancer
Dec 2020
-
Healing lungs, improving data, oncology research and more
June 2020